Shamburg News · 8-K filed Nov 16, 2026, 8:08 AM EST
Corbus Pharmaceuticals Presents Additional CANYON-1 Phase 1b Data for CRB-913 Obesity Drug
CRBP · Corbus Pharmaceuticals Holdings, Inc.
- Other event
- Reg FD disclosure
- Other
- Materiality: medium
On November 16, 2026, Corbus Pharmaceuticals Holdings, Inc. announced that additional CANYON-1 Phase 1b data for CRB-913 in obesity were presented in a poster at ObesityWeek 2026 in Washington, D.C. The filing reports a mean weight loss of 5.0% at 12 weeks in the 60 mg cohort, a treatment discontinuation rate due to adverse events of 8.3%, and no serious or severe psychiatric adverse events. The Company also furnished an updated investor presentation and plans to engage with the FDA on development plans.
Source: SEC EDGAR, Form 8-K, Items 7.01, 8.01, 9.01, accession 0001193125-26-462186.
Written from the filing by Shamburg Markets. Figures are as reported by the company.